文章核心观点 - 证券法律公司Bleichmar Fonti & Auld LLP宣布对Elanco Animal Health Incorporated及其部分高级管理人员提起诉讼，指控其可能违反联邦证券法 [1] - 投资者需在2024年12月6日前向法院申请成为案件的主要原告 [2] 公司信息 - Elanco Animal Health Incorporated是一家开发动物疾病治疗产品的公司，其两个重要产品Zenrelia和Credelio Quattro正在接受美国食品药品监督管理局（FDA）的审查 [3] - 公司曾表示FDA拥有所有必要数据以完成审查，并预计在2024年6月底前批准这些药物，但2024年6月27日宣布FDA不会在6月批准这些药物，且Zenrelia将附带安全警告 [4] - 由于此消息，Elanco的股价从2024年6月26日的每股17.97美元下跌至2024年6月27日的每股14.27美元，跌幅超过21% [5] 投资者行动 - 投资者可通过访问https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated提交信息，了解可能的法律选项 [6][7][9] - 所有代理均基于胜诉收费，投资者无需承担任何法院费用或诉讼费用 [6] 法律公司信息 - Bleichmar Fonti & Auld LLP是一家领先的国际律师事务所，专注于证券集体诉讼和股东诉讼，2023年被ISS SCAS评为前五名原告律师事务所 [7] - 该公司的律师曾被Law360评为“原告酒吧的巨人”，并被Thompson Reuters评为SuperLawyers [7] - 近期成功案例包括从Tesla, Inc.的董事会追回超过9亿美元（待法院批准），以及从Teva Pharmaceutical Ind. Ltd.追回4.2亿美元 [7]

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

SAN DIEGO, Nov. 25, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024. Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: R ...

文章核心观点 - 公司面临证券集体诉讼，原因是其在2023年11月7日至2024年6月26日期间对Zenrelia和Credelio Quattro的安全性和审批时间表进行了虚假或误导性陈述 [1][5] 公司背景 - 公司是一家动物健康公司，开发宠物和农场动物产品，包括Zenrelia（一种用于犬类皮肤病的口服Janus激酶抑制剂）和Credelio Quattro（一种用于犬类的驱虫剂） [3] 产品审批时间表 - 2023年11月，公司预计Zenrelia和Credelio Quattro将在2024年上半年获得美国食品药品监督管理局（FDA）的批准 [4] - 2024年5月，公司更新了审批时间表，预计Zenrelia将在2024年第三季度获得FDA批准并在第四季度上市，Credelio Quattro将在2024年第三季度获得批准并在第四季度上市 [4] 诉讼指控 - 公司在整个集体诉讼期间，对Zenrelia的安全性进行了虚假或误导性陈述，并错误地预测了Zenrelia和Credelio Quattro的审批和商业化时间表 [5] 公司更新 - 2024年6月27日，公司更新了FDA对Zenrelia和Credelio Quattro的审批时间表，预计Zenrelia的美国标签将包含一个安全警告，这可能会减缓产品在美国的采用曲线，并最初限制Zenrelia可以安全地给狗使用的天数约25% [6] - 公司现在预计Zenrelia将在2024年第三季度获得FDA批准，并在第四季度上市，Credelio Quattro预计将在2024年第四季度获得FDA批准 [6] 市场反应 - 在2024年6月27日的新闻发布后，公司股价下跌了3.69美元，跌幅为20%，收盘价为14.28美元 [7]

GREENFIELD, Ind, Nov. 25, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.On Tuesday, December 3, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Evercore ISI 7th Annual HealthCONx at 11:15 a.m. ET.On Thursday, December 5, Todd Young will participate in the Piper Sandler 36th Annual Healthcare Conference at 1:30 p.m. ET.Live audio webcasts will be available in the "E ...

NEW YORK, Nov. 24, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), of the important December 6, 2024 lead plaintiff deadline.So what: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=112959&from=4C ...